Caribou Biosciences Inc. (CRBU) NASDAQ
$5.14 0.02 (0.39%)
Market Cap: $464.22M
As of 03/28/24 04:00 PM EDT. Market closed.
Caribou Biosciences Inc. (CRBU)
NASDAQ
$5.14
0.02 (0.39%)
Market Cap: $464.22M
As of 03/28/24 04:00 PM EDT. Market closed.
caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or ... read more
caribou biosciences is a leading biotechnology company in genome engineering. we develop technology-based solutions for cellular engineering and analysis based on the crispr-cas9 technology platform. cas9, when paired with a guide rna, cuts double-stranded dna allowing for specific changes to dna. these site-specific dna modifications can be utilized to carry out sophisticated gene knock-outs or knock-ins. caribou's technologies mark a revolutionary development that allows scientists to engineer nearly any part of any genome with extreme flexibility. forbes magazine has called cas9 the protein that "could change biotech forever"? and the new york times has noted that "the pace of new discoveries and applications is dizzying."? caribou's tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. interested in joining our team? please contact us at jobs at cariboub read less
Owner | Relationship | Date | Transaction | Cost | # Shares | Value($) | Total Shares | Form 4 |
Kanner Steven | Chief Scientific Officer | Feb 06, 2024 | Option Exercise | $2.69 | 30,577 | 82,252 | 354,037 | Feb 08, 2024, 05:06 PM |
Haurwitz Rachel E. | President and CEO | Jun 08, 2023 | Option Exercise | $2.96 | 10,000 | 29,600 | 40,000 | Jun 09, 2023, 04:31 PM |
Haurwitz Rachel E. | President and CEO | Mar 20, 2023 | Option Exercise | $2.96 | 10,000 | 29,600 | 30,000 | Mar 22, 2023, 04:16 PM |
Rizvi Syed Ali-aamir | Chief Medical Officer | Jan 19, 2023 | Sale | $6.31 | 5,627 | 35,506 | 59,373 | Jan 20, 2023, 04:13 PM |
Kanner Steven | Chief Scientific Officer | Dec 02, 2022 | Option Exercise | $2.69 | 21,401 | 57,569 | 323,460 | Dec 02, 2022, 07:01 PM |
Fischesser Ryan | VP of Finance and Controller | Oct 06, 2022 | Option Exercise | $3.40 | 5,678 | 19,305 | 116,044 | Oct 07, 2022, 05:13 PM |
Fischesser Ryan | VP of Finance and Controller | Oct 06, 2022 | Sale | $10.80 | 10,000 | 107,958 | 110,366 | Oct 07, 2022, 05:13 PM |
MCCLUNG BARBARA G | Chief Legal Officer | Sep 15, 2022 | Option Exercise | $2.69 | 27,595 | 74,231 | 376,566 | Sep 16, 2022, 04:14 PM |
Kanner Steven | Chief Scientific Officer | Aug 25, 2022 | Option Exercise | $2.69 | 43,248 | 116,337 | 345,307 | Aug 26, 2022, 05:42 PM |
Kanner Steven | Chief Scientific Officer | Aug 25, 2022 | Sale | $11.22 | 43,248 | 485,221 | 302,059 | Aug 26, 2022, 05:42 PM |
Kanner Steven | Chief Scientific Officer | May 13, 2022 | Option Exercise | $1.88 | 74,420 | 140,081 | 302,059 | May 17, 2022, 08:51 PM |
Haurwitz Rachel E. | President and CEO | May 09, 2022 | Option Exercise | $2.96 | 10,000 | 29,600 | 20,000 | May 10, 2022, 07:32 PM |
Haurwitz Rachel E. | President and CEO | Jan 26, 2022 | Option Exercise | $2.96 | 10,000 | 29,600 | 10,000 | May 10, 2022, 07:29 PM |
Fischesser Ryan | VP of Finance and Controller | May 05, 2022 | Option Exercise | $3.40 | 2,274 | 7,733 | 115,518 | May 06, 2022, 07:28 PM |
Fischesser Ryan | VP of Finance and Controller | Mar 15, 2022 | Option Exercise | $3.40 | 2,274 | 7,733 | 113,244 | Mar 17, 2022, 07:14 PM |
Kanner Steven | Chief Scientific Officer | Mar 04, 2022 | Option Exercise | $2.90 | 10,720 | 31,036 | 227,639 | Mar 07, 2022, 07:58 PM |
O'Byrne Jason | Chief Financial Officer | Feb 08, 2022 | Option Exercise | $4.11 | 24,336 | 100,021 | 24,336 | Feb 08, 2022, 07:27 PM |
Haurwitz Rachel E. | President and CEO | Jan 26, 2022 | Option Exercise | $2.96 | 10,000 | 29,600 | 3,359,395 | Jan 27, 2022, 04:41 PM |
Fischesser Ryan | VP of Finance and Controller | Jan 11, 2022 | Buy | $4.00 | 7,387 | 29,553 | 109,082 | Jan 12, 2022, 04:35 PM |
Fischesser Ryan | VP of Finance and Controller | Dec 20, 2021 | Buy | $2.69 | 1,136 | 3,056 | 101,695 | Dec 21, 2021, 05:23 PM |
MCCLUNG BARBARA G | Chief Legal Officer | Dec 07, 2021 | Buy | $2.69 | 6,127 | 16,482 | 348,971 | Dec 08, 2021, 06:06 PM |
MCCLUNG BARBARA G | Chief Legal Officer | Oct 20, 2021 | Buy | $2.69 | 9,219 | 24,799 | 342,844 | Oct 21, 2021, 06:12 PM |
Kanner Steven | Chief Scientific Officer | Oct 12, 2021 | Buy | $1.92 | 114,860 | 220,757 | 215,031 | Oct 13, 2021, 07:31 PM |
Fischesser Ryan | VP of Finance and Controller | Oct 11, 2021 | Buy | $2.69 | 1,746 | 4,697 | 100,559 | Oct 12, 2021, 07:33 PM |
Owner | Relationship | Date | Value($) |
Kanner Steven | Chief Scientific Officer | 02/06/2024 | 82,252 |
Haurwitz Rachel E. | President and CEO | 06/08/2023 | 29,600 |
Haurwitz Rachel E. | President and CEO | 03/20/2023 | 29,600 |
Rizvi Syed Ali-aamir | Chief Medical Officer | 01/19/2023 | 35,506 |
Kanner Steven | Chief Scientific Officer | 12/02/2022 | 57,569 |
Fischesser Ryan | VP of Finance and Controller | 10/06/2022 | 19,305 |
Fischesser Ryan | VP of Finance and Controller | 10/06/2022 | 107,958 |
MCCLUNG BARBARA G | Chief Legal Officer | 09/15/2022 | 74,231 |
Kanner Steven | Chief Scientific Officer | 08/25/2022 | 116,337 |
Kanner Steven | Chief Scientific Officer | 08/25/2022 | 485,221 |
Kanner Steven | Chief Scientific Officer | 05/13/2022 | 140,081 |
Haurwitz Rachel E. | President and CEO | 05/09/2022 | 29,600 |
Haurwitz Rachel E. | President and CEO | 01/26/2022 | 29,600 |
Fischesser Ryan | VP of Finance and Controller | 05/05/2022 | 7,733 |
Fischesser Ryan | VP of Finance and Controller | 03/15/2022 | 7,733 |
Kanner Steven | Chief Scientific Officer | 03/04/2022 | 31,036 |
O'Byrne Jason | Chief Financial Officer | 02/08/2022 | 100,021 |
Haurwitz Rachel E. | President and CEO | 01/26/2022 | 29,600 |
Fischesser Ryan | VP of Finance and Controller | 01/11/2022 | 29,553 |
Fischesser Ryan | VP of Finance and Controller | 12/20/2021 | 3,056 |
MCCLUNG BARBARA G | Chief Legal Officer | 12/07/2021 | 16,482 |
MCCLUNG BARBARA G | Chief Legal Officer | 10/20/2021 | 24,799 |
Kanner Steven | Chief Scientific Officer | 10/12/2021 | 220,757 |
Fischesser Ryan | VP of Finance and Controller | 10/11/2021 | 4,697 |
Fund | # Shares Owned | % of Portfolio | % Change | Investing Style |
---|---|---|---|---|
BLACKROCK INC. | 7,068,468 | 0.00103% | 16.17% | Other |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 3,500,000 | 0.37% | Exited | Other |
GEODE CAPITAL MANAGEMENT, LLC | 1,794,648 | 0.00108% | 13.79% | Other |
CANDRIAM S.C.A. | 860,024 | 0.03% | New | Other |
MAVERICK CAPITAL LTD | 652,542 | 0.08% | No change | Growth At A Reasonable Price, Growth |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 203,933 | 0.00242% | -19.69% | Other |
ROYCE & ASSOCIATES LP | 253,102 | 0.01% | 940.93% | Value |
BRUCE & CO., INC. | 200,000 | 0.4% | No change | Value |
RENAISSANCE TECHNOLOGIES LLC | 32,400 | 0.00029% | New | Other |
PENTWATER CAPITAL MANAGEMENT LP | 10,000 (Call) | 0.00026% | Exited | Event Driven |
Period of Report: 12/31/2023
10-K/10-Q Filings: View